OBJECTIVES: to assess the treatment pattern, dosage and costs of lanreotide AUTOGEL 120 (L-ATG120) administered as part of routine acromegaly care in Poland. METHODS: Lanro-Study is a multicenter, non-interventional, observational study on resource utilization in the population of Polish acromegalic patients treated with L-ATG120 at 4 weeks or extended (>4 weeks) dosing interval. The study recruited adult acromegalic patients treated medically for ≥ 1 year, including at least 3 injections of L-ATG120. Data on dosing interval and aspects of administration were collected prospectively during 12-months (interim analysis). Costs were calculated in PLN  from the public health-care payer perspective for the year 2013 (1 EURO = 4.2 PLN).  RESULTS: 139 patients were included in the analysis. Changes in dosing regimen were reported in 14 (9.4% ) patients, polytherapy was used in 11 (8%) patients. 70 patients (50%) received L-ATG120 at an extended dosing interval (>4 weeks), the mean number of days between injections was 35.56 (SD 8.4). L-ATG120 was predominantly administered in out-patient setting (77%), by health-care professionalists (94%). Mean time needed for preparation and administration was 4.33 and 1.58 min., respectively, mean product wastage – 0.13 mg. The cost of L-ATG120 was estimated at 4103.87 PLN/patient/month  CONCLUSIONS: These results represent the current use of L-ATG120 in the population of Polish acromegalic patients in a realistic clinical settings. Findings that 50% of patients could be treated with dose intervals of  longer than 28 days support the potential for L-ATG120 of reducing treatment burden.